OBJECTIVE: To examine the stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP) in criterion-related groups. The MSIP is a disease-targeted health impact measure based on a selection of International Classification of Functioning, Disability and Health (ICF) aspects selected by 98 patients and medical and non-medical health professionals. METHOD: Data were obtained from a postal survey of 377 individuals with Multiple Sclerosis (MS) attending the MS centre of the University Medical Center Groningen (UH) and 153 subjects from the MS patients' association. Stability was tested with t-tests for paired samples and intraclass correlation coefficients for repeated measures in a sample of 251 individuals from the UH sample. The Relative Validity (RV) was estimated using the Short Form Questionnaire (SF-36), the World Health Organization Quality of Life-BREF (WHOQOL-BREF), the Disability and Impact Profile (DIP), the Impact on Autonomy Questionnaire (IPAQ) and the Groningen Activity Restriction Scale (GARS). RESULTS: These indicate that the MSIP is a stable measure in time. MSIP scales showed satisfactory and strong RV. In general, the domain-specific activities and participation measures (GARS and IPAQ) performed equally or slightly better than the comparable MSIP-scales, while the MSIP performed better than the multidimensional health impact measures (SF-36, DIP and WHOQOL-BREF). CONCLUSION: The MSIP demonstrated good stability and RV compared to generic health impact and domain-specific measures.
OBJECTIVE: To examine the stability and relative validity of the Multiple Sclerosis Impact Profile (MSIP) in criterion-related groups. The MSIP is a disease-targeted health impact measure based on a selection of International Classification of Functioning, Disability and Health (ICF) aspects selected by 98 patients and medical and non-medical health professionals. METHOD: Data were obtained from a postal survey of 377 individuals with Multiple Sclerosis (MS) attending the MS centre of the University Medical Center Groningen (UH) and 153 subjects from the MSpatients' association. Stability was tested with t-tests for paired samples and intraclass correlation coefficients for repeated measures in a sample of 251 individuals from the UH sample. The Relative Validity (RV) was estimated using the Short Form Questionnaire (SF-36), the World Health Organization Quality of Life-BREF (WHOQOL-BREF), the Disability and Impact Profile (DIP), the Impact on Autonomy Questionnaire (IPAQ) and the Groningen Activity Restriction Scale (GARS). RESULTS: These indicate that the MSIP is a stable measure in time. MSIP scales showed satisfactory and strong RV. In general, the domain-specific activities and participation measures (GARS and IPAQ) performed equally or slightly better than the comparable MSIP-scales, while the MSIP performed better than the multidimensional health impact measures (SF-36, DIP and WHOQOL-BREF). CONCLUSION: The MSIP demonstrated good stability and RV compared to generic health impact and domain-specific measures.
Authors: Peter Joseph Jongen; Bertil F M Blok; John P Heesakkers; Marco Heerings; Wim A Lemmens; Rogier Donders Journal: Health Qual Life Outcomes Date: 2015-10-30 Impact factor: 3.186
Authors: Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; J Coby Baart; Leo H Visser; Edo P Arnoldus; H Jacobus Gilhuis; Paul Pop; Monique Booy; Wim Lemmens; Rogier Donders; Anton Kool; Esther van Noort Journal: Patient Prefer Adherence Date: 2015-12-11 Impact factor: 2.711
Authors: Peter Joseph Jongen; Ioanna Stavrakaki; Bernard Voet; Erwin Hoogervorst; Erik van Munster; Wim H Linssen; Ludovicus G Sinnige; Wim I Verhagen; Leo H Visser; Ruud van der Kruijk; Freek Verheul; Jan Boringa; Marco Heerings; Werner Gladdines; Fredrik Lönnqvist; Pieter Gaillard Journal: J Neurol Date: 2016-06-07 Impact factor: 4.849
Authors: Peter Joseph Jongen; Ingrid E H Kremer; Elena Hristodorova; Silvia M A A Evers; Anton Kool; Esther M van Noort; Mickaël Hiligsmann Journal: J Med Internet Res Date: 2017-07-21 Impact factor: 5.428
Authors: Peter Joseph Jongen; Marco Heerings; Wim A Lemmens; Rogier Donders; Anneke van der Zande; Esther van Noort; Anton Kool Journal: BMC Neurol Date: 2015-08-04 Impact factor: 2.474
Authors: Peter Joseph Jongen; Ludovicus G Sinnige; Björn M van Geel; Freek Verheul; Wim I Verhagen; Ruud A van der Kruijk; Reinoud Haverkamp; Hans M Schrijver; Jacoba C Baart; Leo H Visser; Edo P Arnoldus; Herman Jacobus Gilhuis; Paul Pop; Monique Booy; Marco Heerings; Anton Kool; Esther van Noort Journal: Patient Prefer Adherence Date: 2016-03-03 Impact factor: 2.711